Literature DB >> 6169650

Lymphokine production by PHA-stimulated human lymphocytes is enhanced by interferon.

H Blomgren, S Einhorn.   

Abstract

Human interferon (IFN) was examined for its capacity to modify the phytohaemagglutinin (PHA)-triggered release of mitogenic factors (MF) from human lymphocytes in vitro. It was observed that the presence of partially purified leukocyte IFN (IFN-alpha) during the PHA pulsing of lymphocytes increased their subsequent release of factors which were mitogenic for fractionated T cells. A similar effect was also observed when lymphocytes were exposed to IFN-alpha prior to PHA pulsing. The possibility that substances in the IFN preparations other than IFN are responsible for the above effect is ruled out by the finding that a pure fibroblast IFN (IFN-beta) preparation also augmented the MF release by PHA-pulsed lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6169650     DOI: 10.1159/000232816

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  4 in total

1.  Inhibitory versus stimulatory effects of natural human interferon-alpha on proliferation of lymphocyte subpopulations.

Authors:  V Holán; S Nakamura; J Minowada
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

Review 2.  Interferon treatment of human malignancies--a short review.

Authors:  S Einhorn; H Strander
Journal:  Med Oncol Tumor Pharmacother       Date:  1993

3.  Decrease in the phagocytic activity of peripheral monocytes in patients treated with human interferon-alpha.

Authors:  S Einhorn; C Jarstrand
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

4.  Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma.

Authors:  P Hersey; E Hasic; M MacDonald; A Edwards; A Spurling; A S Coates; G W Milton; W H McCarthy
Journal:  Br J Cancer       Date:  1985-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.